Breakthrough Prostate Cancer Treatment Proven Effective in Real World Study
A large French study supports the safety and effectiveness of PSMA-targeted radiopharmaceutical therapy for advanced prostate cancer in routine clinical practice.

Prostate-Specific Membrane Antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with metastatic Castration-Resistant Prostate Cancer (mCRPC) in routine clinical practice, consistent with outcomes from the landmark VISION trial. An analysis of outcomes from a French early-access programme, the largest real-world cohort of patients studied to date, confirms the therapy’s benefit-risk profile while also shedding light on patient selection and treatment-use trends. The research was published in The Journal of Nuclear Medicine.
PSMA-targeted radiopharmaceutical therapy has emerged as a novel treatment for patients with mCRPC whose disease has progressed despite standard therapies. The treatment was studied extensively in the VISION clinical trial and, in 2022, {177})Lu-PSMA-617 became the first radiopharmaceutical therapy approved for the treatment of prostate cancer.
“Although the VISION clinical trial demonstrated the safety and efficacy of 177Lu-PSMA-617 in a selected population, there is a need for complementary real-world data to understand its use and outcomes in routine clinical practice among broader and more diverse patient populations,” said Clément Bailly, MD, a nuclear medicine physician at Nantes University Hospital in France. “France’s early-access programme provided a valuable opportunity to evaluate the safety and efficacy of 177Lu-PSMA-617 in a real-world setting.”
From December 2021 – April 2025, the early-access programme enrolled 3,709 patients with mCRPC across 46 centres in France. All patients had progressive disease after receiving at least one standard treatment. Through the programme, patients received up to six cycles of 177Lu-PSMA-617. Clinical evaluations, prostate-specific antigen (PSA) levels, imaging assessments and treatment-related adverse events were recorded during regular follow-up. Progression-free survival and overall survival were assessed and compared with the outcomes of the VISION trial.
Patients in the early-access programme were older, had received more previous treatments and had more lymph node metastases, but lower baseline PSA levels, than those in the VISION trial. Median progression-free survival was 7.6 months, compared with 8.7 months in VISION. Based on PSA criteria, disease control was achieved in 82% of the French cohort.
The early-access programme also provided further insight into several important findings. Subgroup analyses confirmed efficacy in older patients and showed more favourable outcomes in patients who had received less taxane-based chemotherapy.
A “flare-up” phenomenon was also observed in some patients, who experienced a rise in Prostate-Specific Antigen (PSA) levels after the first cycle of 177Lu-PSMA-617, followed by a decline after the second cycle. Clinicians also increasingly treated patients with less advanced disease and less previous treatment exposure. This suggests that, as experience with radiopharmaceutical therapy grew, clinicians became more comfortable introducing it earlier in the treatment pathway.
“This real-world data confirms that the benefits seen in the VISION trial translate into routine clinical practice,” said Guilhem Roubaud, MD, a medical oncologist at Institut Bergonié in Bordeaux, France. “For patients with advanced prostate cancer, this study means earlier access to a potentially life-extending treatment when options are limited, adding value to the French Early Access programme in delivering both rapid access to innovation and robust evidence to inform future clinical practice for patients and healthcare decisions whenever possible.”